Your search for: 'author:("Hartikainen, Päivi")' has returned 12 results. (0.073s) Save search

Authors: Seppälä, Toni T. | Koivisto, Anne M. | Hartikainen, Päivi | Helisalmi, Seppo | Soininen, Hilkka | Herukka, Sanna-Kaisa

Article Type: Research Article

Abstract: Longitudinal changes of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) have been studied, but there are few consistent conclusions and even less is known about their variation during the different stages of the disease. We hypothesized that changes in CSF biomarker values would correlate with the progression of the cognitive decline in AD. One hundred and thirty-one memory clinic patients [56 AD, 57 mild cognitive impairment (MCI), 10 other neurological disorders, eight unimpaired subjects] underwent a clinical follow-up with repeated Mini-Mental Status Examination (MMSE) tests and two lumbar punctures with a median interval of 3 years. Levels of CSF …amyloid-β (Aβ)42 , tau, and p-tau-181 were measured using commercially available ELISA. Twenty-one of the MCI subjects progressed to AD, whereas 26 subjects remained stable and 56 subjects had AD already at the baseline. The subjects displaying the most rapid MMSE decline rate had the lowest baseline Aβ42 , highest tau, and highest p-tau-181 CSF concentrations. An annual decrease of 2.20 pg/ml/year in the CSF p-tau-181 concentration was seen in AD-AD patients (p = 0.001). The difference was significant compared to stable MCI-MCI (increase of 1.24 pg/ml/year, p = 0.001) and cognitively healthy (increase of 0.84 pg/ml/year, p = 0.013) subjects (p for group difference 0.004). The decrease rate of p-tau-181 correlated with the MMSE decrease rate in AD subjects (r = 0.579, p < 0.001). The CSF Aβ42 level decreased in the AD-AD group (decrease 11.9 pg/ml/year, p < 0.001). Concentrations of hyperphosphorylated tau decline in the late stages of the AD process. The decrease of p-tau-181 appears to correlate with cognitive functioning and probably reflects neuronal loss. More longitudinal studies of CSF biomarker dynamics are needed, especially in patients during the preclinical stage of the disease. Show more

Keywords: Alzheimer's disease, amyloid, biomarker, cerebrospinal fluid, CSF, longitudinal, mild cognitive impairment, tau

DOI: 10.3233/JAD-2011-101911

Citation: Journal of Alzheimer's Disease, vol. 25, no. 4, pp. 583-594, 2011

Authors: Katisko, Kasper | Krüger, Johanna | Soppela, Helmi | Hartikainen, Päivi | Haapasalo, Annakaisa | Remes, Anne M. | Solje, Eino

Article Type: Research Article

Abstract: Background: Due to the significant presence of neuropsychiatric symptoms in patients with frontotemporal dementia (FTD) spectrum disorders, psychiatric misdiagnoses, diagnostic delay, and use of psychiatric treatments are common prior to the FTD diagnosis. Furthermore, treatment of diagnosed FTD patients mainly relies on off-label psychopharmacological approaches. Currently, limited real-world data are available regarding the actual use of psychopharmacological medications in FTD. Objective: To evaluate psychopharmacological medication use at the time of FTD diagnosis. Methods: Psychopharmacological medication use was evaluated in a Finnish FTD cohort containing 222 FTD patients, including the major clinical disease phenotypes (behavioral, language, and motor variants) and genetic …patients carrying the C9orf72 repeat expansion. A cohort of 214 Alzheimer’s disease (AD) patients was used as a neurodegenerative disease reference group. Results: Active use of psychopharmacological medications at the time of diagnosis was significantly more common in FTD compared to AD, especially in the case of antidepressants (26.1% versus 15.0%, OR = 2.01, p  = 0.008), antipsychotics (23.9% versus 9.3%, OR = 3.15, p  < 0.001), and mood-stabilizers (6.3% versus 1.9%, OR = 2.93, p  = 0.085; not statistically significant), whereas the use of cholinesterase inhibitors or memantine was nearly nonexistent in FTD patients. Female gender and behavioral variant of FTD phenotype alongside with depressive and psychotic symptoms were the most prominent factors associating with the use of these medications among the FTD spectrum patients. Conclusion: Use of off-label psychopharmacological medication and polypharmacy is substantially common at the time of FTD diagnosis. This likely reflects the challenges in using symptom-driven treatment approaches, especially prior to the eventual diagnosis. Show more

Keywords: Alzheimer’s disease, frontotemporal dementia, pharmacology, psychiatry, psychopharmacology, therapeutics

DOI: 10.3233/JAD-230494

Citation: Journal of Alzheimer's Disease, vol. 95, no. 2, pp. 677-685, 2023

Authors: Hartikainen, Päivi | Räsänen, Janne | Julkunen, Valtteri | Niskanen, Eini | Hallikainen, Merja | Kivipelto, Miia | Vanninen, Ritva | Remes, Anne M. | Soininen, Hilkka

Article Type: Research Article

Abstract: Cortical thickness analysis has been proposed as a potential diagnostic measure in memory disorders. In this retrospective study, we compared the cortical thickness values of 24 patients with frontotemporal dementia (FTD) to those of 25 healthy controls, 45 symptomatic subjects with stable mild cognitive impairment (S-MCI), 15 subjects with progressive mild cognitive impairment (P-MCI), and 36 patients with Alzheimer's disease (AD). The patterns of regions of thinning in FTD when compared to controls and also S-MCI patients showed similar trends; thinning of the bilateral frontal poles and bilateral medial temporal lobe structures, especially the anterior part of the gingulum, the …uncus, and parahippocampal gyri. Cortical thinning in FTD was also found on the boundary regions of parietal and occipital lobes. In the P-MCI group compared to FTD, the trend of thinning in small distinct areas of the parietal and occipital lobes was observed. The FTD and AD groups did not differ statistically, but we found trends toward thinning in FTD of the left cingulate gyrus, and the left occipitotemporal gyri, and in AD of the inferior parietal, occipitoparietal, and the pericalcarine regions, more in the right hemisphere. In FTD, increased slowness in the executive test (Trail-Making A) correlated with the thinner cortex, whereas the language tests showed the lower scores, the thinner cortex in the left hemisphere. Cortical thickness might be a tool for detecting subtle changes in brain atrophy in screening of dementia prior to the development of diffuse or lobar atrophies. Show more

Keywords: Alzheimer's disease, cortical thickness analysis, frontotemporal dementia, magnetic resonance imaging, mild cognitive impairment

DOI: 10.3233/JAD-2012-112060

Citation: Journal of Alzheimer's Disease, vol. 30, no. 4, pp. 857-874, 2012

Authors: Soppela, Helmi | Krüger, Johanna | Hartikainen, Päivi | Koivisto, Anne | Haapasalo, Annakaisa | Borroni, Barbara | Remes, Anne M. | Katisko, Kasper | Solje, Eino

Article Type: Research Article

Abstract: Background: Currently, there are few studies considering possible modifiable risk factors of frontotemporal dementia (FTD). Objective: In this retrospective case-control study, we evaluated whether a history of traumatic brain injury (TBI) associates with a diagnosis of FTD or modulates the clinical phenotype or onset age in FTD patients. Methods: We compared the prevalence of prior TBI between individuals with FTD (N = 218) and age and sex-matched AD patients (N = 214) or healthy controls (HC; N = 100). Based on the patient records, an individual was categorized to the TBI+ group if they were reported to have suffered from TBI during lifetime. The possible associations …of TBI with age of onset and disease duration were also evaluated in the whole FTD patient group or separately in the sporadic and genetic FTD groups. Results: The prevalence of previous TBI was the highest in the FTD group (19.3%) when compared to the AD group (13.1%, p  = 0.050) or HC group (12%, p  = 0.108, not significant). Preceding TBI was more often associated with the sporadic FTD cases than the C9orf72 repeat expansion-carrying FTD cases (p  = 0.003). Furthermore, comparison of the TBI+ and TBI- FTD groups indicated that previous TBI was associated with an earlier onset age in the FTD patients (B = 3.066, p  = 0.010). Conclusion: A preceding TBI associates especially with sporadic FTD and with earlier onset of symptoms. The results of this study suggest that TBI may be a triggering factor for the neurodegenerative processes in FTD. However, understanding the precise underlying mechanisms still needs further studies. Show more

Keywords: Comorbidity, dementia, frontotemporal dementia, head trauma, risk factors, traumatic brain injury

DOI: 10.3233/JAD-220545

Citation: Journal of Alzheimer's Disease, vol. 91, no. 1, pp. 225-232, 2023

Authors: Haapanen, Marjut | Katisko, Kasper | Hänninen, Tuomo | Krüger, Johanna | Hartikainen, Päivi | Haapasalo, Annakaisa | Remes, Anne M. | Solje, Eino

Article Type: Short Communication

Abstract: Primary progressive aphasia (PPA) forms the spectrum of language variants of frontotemporal lobar degeneration (FTLD), including three subtypes each consisting of distinctive speech and language features. Repeat expansion in C9orf72 gene is the most common genetic cause of FTLD. However, thus far only little is known about the effects of the C9orf72 repeat expansion on the phenotype of PPA. This retrospective study aimed at determining the differences between the PPA phenotypes of the C9orf72 expansion carriers and non-carriers. Our results demonstrated no significant differences between these groups, indicating that the C9orf72 repeat expansion does not substantially affect the phenotype of …PPA. Show more

Keywords: C9orf72, frontotemporal dementia, frontotemporal lobar degeneration, primary progressive aphasia

DOI: 10.3233/JAD-200795

Citation: Journal of Alzheimer's Disease, vol. 78, no. 3, pp. 919-925, 2020

Authors: Suhonen, Noora-Maria | Haanpää, Ramona M. | Korhonen, Ville | Jokelainen, Jari | Pitkäniemi, Anni | Heikkinen, Anna-Leena | Krüger, Johanna | Hartikainen, Päivi | Helisalmi, Seppo | Hiltunen, Mikko | Hänninen, Tuomo | Remes, Anne M.

Article Type: Research Article

Abstract: While the C9ORF72 expansion is a major cause of behavioral variant frontotemporal dementia (bvFTD), little is known of the resultant cognitive profile. Our aim was to characterize the neuropsychological profile of the C9ORF72 associated bvFTD. We contrasted structured neuropsychological assessments of the C9ORF72 expansion carrier bvFTD patients (n  = 26) with non-carrier bvFTD patients (n  = 47) and those with Alzheimer’s disease (AD) (n  = 47). As compared to the non-carrier bvFTD patients, the C9ORF72 expansion carriers performed at a higher level in an immediate verbal memory test while showing poorer phonemic verbal fluency. Additionally, the expansion carriers committed more errors in the …Stroop test and the Alternating S task relative to the non-carriers. Finally, while the AD patients outperformed both bvFTD patient groups in working memory, their performance was more impaired in episodic memory tasks relative to the bvFTD groups. We conclude that bvFTD patients carrying the C9ORF72 expansion may display more pronounced executive deficits together with less severe verbal memory impairment as compared to their non-carrier bvFTD counterparts. Knowledge of the specific neuropsychological features associated with the C9ORF72 related bvFTD may aid in the early diagnosis of the disease as well as in targeting genetic testing. Show more

Keywords: Alzheimer’s disease, C9ORF72, frontotemporal dementia, frontotemporal lobar degeneration, genetics, neuropsychological tests, progressive aphasia, semantic dementia

DOI: 10.3233/JAD-161142

Citation: Journal of Alzheimer's Disease, vol. 58, no. 2, pp. 479-489, 2017

Authors: Muñoz-Ruiz, Miguel Ángel | Hartikainen, Päivi | Hall, Anette | Mattila, Jussi | Koikkalainen, Juha | Herukka, Sanna-Kaisa | Julkunen, Valtteri | Vanninen, Ritva | Liu, Yawu | Lötjönen, Jyrki | Soininen, Hilkka

Article Type: Research Article

Abstract: Background: Disease State Index and Disease State Fingerprint represent a novel tool which collates data information from different sources, helping the clinician in the diagnosis and follow-up of dementia diseases. It has been demonstrated that it is applicable in the diagnosis of Alzheimer’s disease (AD). Objective: We applied this novel tool to classify frontotemporal dementia (FTD) cases in comparison with controls, AD, and mild cognitive impairment (MCI) subjects. Methods: Thirty seven patients with FTD, 35 patients with AD, 26 control subjects, and 64 subjects with MCI were included in the study. The Disease State Index encompassed data from cognitive performance …assessed by Mini-Mental State Examination, cerebrospinal fluid biomarkers, MRI volumetric and morphometric parameters as well as APOE genotype. Results: We applied the Disease State Index for comparisons at the group level. The data showed that FTD patients could be differentiated with a high accuracy, sensitivity, and specificity from controls (0.84, 0.84, 0.83) and from MCI (0.79, 0.78, 0.80). However, the correct accuracy was lower in the FTD versus AD comparison (0.69, 0.70, 0.71). In addition, we demonstrated the use of Disease State Fingerprint by comparing one particular FTD case with control, AD, and MCI population data. Conclusion: The results suggest that the Disease State Fingerprint and the underlying Disease State Index are particularly useful in differentiating between normal status and disease in patients with dementia, but it may also help to distinguish between the two dementia diseases, FTD and AD. Show more

Keywords: Alzheimer's disease, cognition, frontotemporal dementia, memory, mild cognitive impairment

DOI: 10.3233/JAD-122260

Citation: Journal of Alzheimer's Disease, vol. 35, no. 4, pp. 727-739, 2013

Authors: Katisko, Kasper | Haapasalo, Annakaisa | Koivisto, Anne | Krüger, Johanna | Hartikainen, Päivi | Korhonen, Ville | Helisalmi, Seppo | Herukka, Sanna-Kaisa | Remes, Anne M. | Solje, Eino

Article Type: Research Article

Abstract:  Several studies have reported reduced risk of cancer in patients with Alzheimer’s disease (AD) or Parkinson’s disease. The relationship between cancer and frontotemporal lobar degeneration (FTLD) has not been previously reported. Here, our aim was to evaluate the occurrence of cancer in Finnish FTLD patients with a high proportion of C9ORF72 repeat expansion carriers in comparison to age- and sex-matched group of AD patients and control subjects classified as not cognitively impaired (NCI). The prevalence of cancer was 9.7% in FTLD, 18.7% in AD, and 17.4% in NCI (FTLD versus AD p  = 0.012, FTLD versus NCI p  = 0.029) groups. No …differences were observed between C9ORF72 repeat expansion carriers and non-carriers inside the FTLD group. To our knowledge, this is the first study showing significantly lower prevalence of cancer in FTLD patients compared to patients with AD or NCI subjects. Our data suggest an inverse association between neurodegeneration and cancer and that FTLD-specific mechanisms may underlie the especially strong inverse association observed in this study. Show more

Keywords: C9ORF72, cancer, comorbidity, frontotemporal dementia, frontotemporal lobar degeneration

DOI: 10.3233/JAD-170854

Citation: Journal of Alzheimer's Disease, vol. 62, no. 2, pp. 789-794, 2018

Authors: Katisko, Kasper | Kokkonen, Nina | Krüger, Johanna | Hartikainen, Päivi | Koivisto, Anne M. | Helisalmi, Seppo | Korhonen, Ville E. | Kokki, Merja | Tuusa, Jussi | Herukka, Sanna-Kaisa | Solje, Eino | Haapasalo, Annakaisa | Tasanen, Kaisa | Remes, Anne M.

Article Type: Research Article

Abstract: Recent studies have shown an epidemiological and immunological association between bullous pemphigoid (BP) and several neurological or psychiatric diseases. Here, our aim was for the first time to specify whether an association exists between BP and frontotemporal lobar degeneration (FTLD). Medical histories of FTLD patients (N = 196) were screened for clinical comorbidity, and BP180 and BP230 autoantibodies were analyzed in the sera of FTLD patients (N = 70, including 24 C9orf72 repeat expansion carriers) by BP180-NC16A-ELISA and BP230-ELISA. One FTLD patient (C9orf72 repeat expansion carrier) had a comorbid diagnosis of BP. Increased levels of serum BP180 autoantibodies (cutoff value …>9 U/ml) were detected more often in FTLD patients (10.0%) than in controls (4.9%). Moreover, elevated levels of both BP180 and BP230 autoantibodies were found more often in C9orf72 repeat expansion-carrying FTLD than non-carrying patients or controls. However, none of these differences reached a statistical significance likely due to our limited cohort size. In conclusion, our findings suggest that subset of FTLD patients especially with the C9orf72 repeat expansion may have an immunological association with BP. Show more

Keywords: Autoantibody, bullous pemphigoid, C9orf72, comorbidity, dementia, frontotemporal dementia, immunology

DOI: 10.3233/JAD-180624

Citation: Journal of Alzheimer's Disease, vol. 66, no. 2, pp. 743-750, 2018

Authors: Jääskeläinen, Olli | Solje, Eino | Hall, Anette | Katisko, Kasper | Korhonen, Ville | Tiainen, Mika | Kangas, Antti J. | Helisalmi, Seppo | Pikkarainen, Maria | Koivisto, Anne | Hartikainen, Päivi | Hiltunen, Mikko | Ala-Korpela, Mika | Soininen, Hilkka | Soininen, Pasi | Haapasalo, Annakaisa | Remes, Anne M. | Herukka, Sanna-Kaisa

Article Type: Research Article

Abstract:  Decreased levels of serum high-density lipoprotein (HDL) cholesterol have previously been linked to systemic inflammation and neurodegenerative diseases, such as Alzheimer’s disease. Here, we aimed to analyze the lipoprotein profile and inflammatory indicators, the high-sensitivity C-reactive peptide (hs-CRP) and glycoprotein acetyls (GlycA), in sporadic and C9orf72 repeat expansion-associated frontotemporal lobar degeneration (FTLD) patients. The C9orf72 hexanucleotide repeat expansion is the most frequent genetic etiology underlying FTLD. The concentrations of different lipid measures in the sera of 67 FTLD patients (15 C9orf72 repeat expansion carriers), including GlycA, were analyzed by nuclear magnetic resonance spectroscopy. To verify the state of systemic inflammation, …hs-CRP was also quantified from patient sera. We found that the total serum HDL concentration was decreased in C9orf72 repeat expansion carriers when compared to non-carriers. Moreover, decreased concentrations of HDL particles of different sizes and subclass were consistently observed. No differences were detected in the very low- and low-density lipoprotein subclasses between the C9orf72 repeat expansion carriers and non-carriers. Furthermore, hs-CRP and GlycA levels did not differ between the C9orf72 repeat expansion carriers and non-carriers. In conclusion, the HDL-related changes were linked with C9orf72 repeat expansion associated FTLD but were not seen to associate with systemic inflammation. The underlying reason for the HDL changes remains unclear. Show more

Keywords: C9orf72 protein, cholesterol, frontotemporal dementia, frontotemporal lobar degeneration, inflammation, lipoproteins

DOI: 10.3233/JAD-190132

Citation: Journal of Alzheimer's Disease, vol. 72, no. 1, pp. 127-137, 2019